Tissuemed is a medical device developer and manufacturer based in
Leeds, UK.
The company was founded in 1985 and developed the first tissue
heart valve (derived from pigs) to receive regulatory approval (CE mark) in Europe. This business was divested in 1999,[1] and the heart values are currently sold by Vascutek, a
Terumo company, under the Aspire brand.[2][3] Thereafter, Tissuemed focused on the development of innovative tissue
adhesives for internal surgical use, including a light activated tissue sealant to prevent blood loss during vascular
anastomosis, the TissueBond system.[4][5]
These products incorporate a unique synthetic
bioadhesive that forms a
covalent bond with tissue proteins, enabling adhesion to internal organs and achieving a sealing effect. In June 2016, Tissuemed won approval from China's FDA for its TissuePatch surgical sealant.[8]
^US patent 6,239,190, "Enhancement of activation for biological tissue adhesives, bonding agents and sealants using "color change" chromophores", published 2001, assigned to Tissuemed Ltd
^Ferroli, P; Acerbi, F; Broggi, M; Schiariti, M; Albanese, E; Tringali, G; Franzini, A; Broggi, G (March–April 2013). "A novel impermeable adhesive membrane to reinforce dural closure: a preliminary retrospective study on 119 consecutive high-risk patients". World Neurosurgery. 79 (3–4): 551–7.
doi:
10.1016/j.wneu.2011.09.022.
PMID22120260.
^Schiariti M, Acerbi F, Broggi M, Tringali G, Raggi A, Broggi G, Ferroli P. Two alternative dural sealing techniques in posterior fossa surgery: (Polylactide-co-glycolide) self-adhesive resorbable membrane versus polyethylene glycol hydrogel. Surg Neurol Int. 2014 Dec 3;5:171. doi: 10.4103/2152-7806.146154.